Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2014

01-04-2014 | Research Article

Walker 256/B malignant breast cancer cells improve femur angioarchitecture and disrupt hematological parameters in a rat model of tumor osteolysis

Authors: Riadh Badraoui, Mariem Boubakri, Maissa Bedbabiss, Hmed Ben-Nasr, Tarek Rebai

Published in: Tumor Biology | Issue 4/2014

Login to get access

Abstract

This study was designed to assess femur angioarchitecture and hematological effects of Walker 256/B cells in a rat model of tumor osteolysis. Tumor osteolysis was induced by in situ inoculation of Walker 256/B malignant cells. Six other rats were sham operated and served as control. Twenty days later, rats were euthanized, and femurs were collected than radiographed. Angioarchitecture [mean lumen diameter (MLD), wall thickness (WTh), Vessel number, volume, and separation (VNb, VV, and VSp respectively)] was studied by histomorphometry at 2 different positions (P1: diaphysis, and P2: metaphysis) of the operated femora. Some hematological parameters were also assessed. Walker 256/B induced marked tumor osteolysis, with cortical perforation and trabecular destruction, associated increase in bone vascularization (increases of VNb and VV and decrease of VSp). Angioarchitecture of W256/B rats was disorganized and showed large MLD and lower WTh. These effects were more prominent in P2. When compared to Sham group, significantly decreases at levels of red blood cell (RBC), hemoglobin (Hb), hematocrit (Ht), and white blood cell (WBC) were observed in W256/B rats. These results suggest that Walker 256/B cells induced tumor osteolysis, improve hypervasculature especially near the tumoral foci (P2) associated hematological disruption. Besides, tumor vessels showed abnormal (enlarged and thinner) and disorganized morphology.
Literature
1.
Kerba M, Wu JS, Duan Q, Hagen NA, Bennett MI. Neuropathic pain features in patients with bone metastases referred for palliative radiotherapy. J Clin Oncol. 2010;28:4892–7.PubMedCrossRef
2.
Fong JE, Le Nihouannen D, Komarova SV. Tumor-supportive and osteoclastogenic changes induced by breast cancer-derived factors are reversed by inhibition of g-secretase. J Biol Chem. 2010;285:31427–34.PubMedCentralPubMedCrossRef
3.
4.
Santini D, Perrone G, Roato I, Godio L, Pantano F, Grasso D, et al. Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related metastases. J Cell Physiol. 2011;226:780–4.
5.
Tiedemann K, Hussein O, Sadvakassova G, Guo Y, Siegel PM, Komarova SV. Breast cancer-derived factors stimulate osteoclastogenesis through the Ca2+/protein kinase C and transforming growth factor-beta/MAPK signaling pathways. J Biol Chem. 2009;284:33662–70.PubMedCentralPubMedCrossRef
6.
Bhat TA, Singh RP. Tumor angiogenesis—a potential target in cancer chemoprevention. Food Chem Toxicol. 2008;46:1334–45.PubMedCrossRef
7.
8.
Sterling JA, Edwards JR, Martin TJ, Mundy GR. Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. Bone 2011;48(1):6–15
9.
Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10:9–22.PubMedCrossRef
10.
Drevs J. VEGF and angiogenesis: implications for breast cancer therapy. Eur J Cancer. 2008;6:7–13.CrossRef
11.
Cackowski FC, Anderson JL, Patrene KD, Choksi RJ, Shapiro SD, Windle JJ, et al. Osteoclasts are important for bone angiogenesis. Blood. 2010;115:140–9.PubMedCrossRef
12.
Collet G, Skrzypek K, Grillon C, Matejuk A, Hafni-Rahbi BE, Lamerant-Fayel N, et al. Hypoxia control to normalize pathologic angiogenesis: potential role for endothelial precursor cells and miRNAs regulation. Vasc Pharmacol. 2012;56:252–61.CrossRef
13.
Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoka M, Yoneda T. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res. 2007;67:4157–63.PubMedCrossRef
14.
Lynch CC. Matrix metalloproteinases as master regulators of the vicious cycle of bone metastasis. Bone. 2011;48:44–53.PubMedCrossRef
15.
Shojaei F. Anti-angiogenesis therapy in cancer: Current challenges and future perspectives. Cancer Lett. 2012;320:130–7.PubMedCrossRef
16.
Heymann D. Anti-RANKL therapy for bone tumours: basic, pre-clinical and clinical evidences. J Bone Oncol. 2012;1:2–11.CrossRef
17.
Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58–62.PubMedCrossRef
18.
Mastro AM, Gay CV, Welch DR. The skeleton as a unique environment for breast cancer cells. Clin Exp Metastasis. 2003;20:275–84.PubMedCrossRef
19.
Bussard KM, Gay CV, Mastro AM. The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev. 2008;27:41–55.PubMedCrossRef
20.
21.
Houssami N, Costelloe CM. Imaging bone metastases in breast cancer: evidence on comparative test accuracy. Ann Oncol. 2012;23:834–43.PubMedCrossRef
22.
Badraoui R, Rebai T. Effect of malignant ascites on antioxidative potency of two tumoral cells-induced bone metastases: Walker 256/B and MatLyLu. Exp Toxicol Pathol. 2012;64:65–8.PubMedCrossRef
23.
Badraoui R, Blouin S, Moreau MF, Gallois Y, Rebai T, Sahnoun Z, et al. Effect of alpha tocopherol acetate in Walker 256/B cells-induced oxidative damage in a rat model of breast cancer skeletal metastases. Chem Biol Interact. 2009;182:98–105.PubMedCrossRef
24.
Mao-Ying QL, Zhao J, Dong ZQ, Wang J, Yu J, Yan MF, et al. A rat model of bone cancer pain induced by intra-tibia inoculation of Walker 256/B mammary gland carcinoma cells. Biochem Biophys Res Commun. 2006;345:1292–8.PubMedCrossRef
25.
Blouin S, Moreau MF, Baslé MF, Chappard D. Relations between radiograph texture analysis and microcomputed tomography in two rat model of bone metastases. Cells Tissues Organs. 2006;182:182–92.PubMedCrossRef
26.
Chappard D, Bouvard B, Baslé MF, Legrand E, Audran M. Bone metastasis: Histological changes and pathophysiological mechanisms in osteolytic or osteosclerotic localizations. A review. Morphologie. 2011;95:65–75.PubMedCrossRef
27.
Chappard D, Libouban H, Legrand E, Ifrah N, Masson C, Baslé MF, et al. Computed microtomography of bone specimens for rapid analysis of bone changes associated with malignancy. Anat Rec. 2010;293:1125–33.CrossRef
28.
29.
Portal-Núñez S, Lozano D, Esbrit P. Role of angiogenesis on bone formation. Histol Histopathol. 2012;27:559–66.PubMed
30.
Nyangoga H, Mercier P, Libouban H, Basle MF, Chappard D. Three-dimensional characterization of the vascular bed in bone metastasis of the rat by microcomputed tomography (MicroCT). PLoS ONE. 2011;6:e17336.PubMedCentralPubMedCrossRef
31.
Etoh T, Inoue H, Tanaka S, Barnard GF, Kitano S, Mori M. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res. 2001;61:2145–53.PubMed
32.
Guise TA, Kozlow WM, Heras-Herig A, Padalecki SS, Yin JJ, Chirgwin JM. Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer. 2005;5:S46–53.PubMedCrossRef
33.
Ellis SL, Grassinger J, Jones A, Camenisch T, Haylock D, Bertoncello I, et al. The relationship between bone, hemopoietic stem cells, and vasculature. Blood. 2011;118:1516–24.PubMedCrossRef
34.
Jiang Y, Bonig H, Ulyagova T, Chang K, Papayannopoulou T. On the adaptation of endosteal stem cell niche function in response to stress. Blood. 2009;114:3773–82.PubMedCentralPubMedCrossRef
35.
Roux S, Mariette X. Hematological malignancies and the bone (myeloma excluded). Joint Bone Spine. 2000;67:264–71.PubMed
36.
Iriuchishima H, Takubo K, Miyakawa Y, Nakamura-Ishizu A, Miyauchi Y, Fujita N, et al. Neovascular niche for human myeloma cells in immunodeficient mouse bone. PLoS ONE. 2012;7:e30557.PubMedCentralPubMedCrossRef
37.
Caolo V, Molin DGM, Post MJ. Notch Regulation of Hematopoiesis, Endothelial Precursor Cells, and Blood Vessel Formation: Orchestrating the Vasculature. Stem Cells Int. 2012 doi:10.​1155/​2012/​805602.
38.
Kwon JH, Shin JH, Kim JH, Gwon DI, Yoon HK, Ko GY, et al. Preoperative transcatheter arterial embolization of hypervascular metastatic tumors of long bones. Acta Radiol. 2010;51:396–401.PubMedCrossRef
39.
Palli D, Berrino F, Vineis P, Tumino R, Panico S, Masala G, et al. A molecular epidemiology project on diet and cancer: the EPIC-Italy prospective study. Design and baseline characteristics of participants. Tumori. 2003;89:586–93.PubMed
40.
De Vizcaya-Ruiz A, Rivero-Muller A, Ruiz-Ramirez L, Howarth JA, Dobrota M. Hematotoxicity response in rats by the novel copper-based anticancer agent: casiopeina II. Toxicology. 2003;194:103–13.PubMedCrossRef
Metadata
Title
Walker 256/B malignant breast cancer cells improve femur angioarchitecture and disrupt hematological parameters in a rat model of tumor osteolysis
Authors
Riadh Badraoui
Mariem Boubakri
Maissa Bedbabiss
Hmed Ben-Nasr
Tarek Rebai
Publication date
01-04-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1485-5

Other articles of this Issue 4/2014

Tumor Biology 4/2014 Go to the issue

Research Article

Association between interleukin-4 -590C > T polymorphism and non-Hodgkin’s lymphoma risk

Research Article

Breast cancer sentinel lymph node mapping using near-infrared guided indocyanine green in comparison with blue dye

Research Article

CCNG2 expression is downregulated in colorectal carcinoma and its clinical significance

Research Article

MDM2 rs2279744 polymorphism and endometrial cancer: a meta-analysis

Research Article

Gly82Ser polymorphism of the receptor for advanced glycation end-product (RAGE) potential high risk in patients with colorectal cancer

Review

A review on the role of l-carnitine in the management of tamoxifen side effects in treated women with breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits